Literature DB >> 23877368

Exercise capacity and ventilatory response during exercise in COPD patients with and without β blockade.

Wilawan Thirapatarapong1, Hilary F Armstrong, Matthew N Bartels.   

Abstract

BACKGROUND: Although β blockade (BB) in patients with chronic obstructive pulmonary disease (COPD) does not show signs of worsening pulmonary function or respiratory symptoms, the effects on cardiopulmonary exercise testing (CPET) remain unclear. The aim of this study was to determine whether BB affects exercise capacity, gas exchange, and hemodynamic responses in patients with COPD.
METHODS: Twenty-four COPD subjects on BB were matched to 24 COPD subjects without BB according to age, gender, body mass index, and severity of COPD. All subjects underwent resting pulmonary function and symptom-limited CPET.
RESULTS: Comparing COPD patients with and without BB revealed that percent peak oxygen consumption and VE/VCO2 nadir were not significantly different (45 ± 16 vs. 51 ± 23 %, p = 0.30, and 35.1 ± 8.5 vs. 36.2 ± 11.6 %, p = 0.69). Systolic blood pressure and heart rate at peak exercise were significantly decreased in COPD patients with BB (168 ± 16 vs. 185 ± 20 mmHg, and 109 ± 16 vs. 122 ± 14 bpm, respectively, p < 0.05).
CONCLUSION: Exercise capacity and gas exchange remain unaffected in patients with COPD in the presence of BB, although heart rate and blood pressure are lower. These findings imply that BB does not adversely affect functional capacity in patients with COPD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23877368     DOI: 10.1007/s00408-013-9492-2

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  41 in total

1.  ATS/ACCP statement on cardiopulmonary exercise testing.

Authors:  Robert M Ross
Journal:  Am J Respir Crit Care Med       Date:  2003-05-15       Impact factor: 21.405

2.  Influence of age, sex, body size, smoking, and beta blockade on key gas exchange exercise parameters in an adult population.

Authors:  Sven Gläser; Beate Koch; Till Ittermann; Christoph Schäper; Marcus Dörr; Stephan B Felix; Henry Völzke; Ralf Ewert; James E Hansen
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2010-08

3.  Lack of ventilatory threshold in patients with chronic obstructive pulmonary disease.

Authors:  J Midorikawa; W Hida; O Taguchi; S Okabe; H Kurosawa; A Mizusawa; H Ogawa; S Ebihara; Y Kikuchi; K Shirato
Journal:  Respiration       Date:  1997       Impact factor: 3.580

4.  Hypertension, exercise, and beta-adrenergic blockade.

Authors:  P A Ades; P G Gunther; C P Meacham; M A Handy; M M LeWinter
Journal:  Ann Intern Med       Date:  1988-10-15       Impact factor: 25.391

5.  Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group.

Authors:  Keith S Naunheim; Douglas E Wood; Zab Mohsenifar; Alice L Sternberg; Gerard J Criner; Malcolm M DeCamp; Claude C Deschamps; Fernando J Martinez; Frank C Sciurba; James Tonascia; Alfred P Fishman
Journal:  Ann Thorac Surg       Date:  2006-08       Impact factor: 4.330

6.  Physician use of beta-adrenergic blocking therapy: a changing perspective.

Authors:  H L Kennedy; R S Rosenson
Journal:  J Am Coll Cardiol       Date:  1995-08       Impact factor: 24.094

7.  Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis.

Authors:  S R Salpeter; T M Ormiston; E E Salpeter; P J Poole; C J Cates
Journal:  Respir Med       Date:  2003-10       Impact factor: 3.415

8.  Normal standards for an incremental progressive cycle ergometer test.

Authors:  N L Jones; L Makrides; C Hitchcock; T Chypchar; N McCartney
Journal:  Am Rev Respir Dis       Date:  1985-05

9.  Lung volumes in healthy nonsmoking adults.

Authors:  R O Crapo; A H Morris; P D Clayton; C R Nixon
Journal:  Bull Eur Physiopathol Respir       Date:  1982 May-Jun

10.  Supplemental oxygen increases arterial stiffness in chronic obstructive pulmonary disease.

Authors:  Matthew N Bartels; Sanja Jelic; Robert C Basner; Pakkay Ngai; John M Gonzalez; Ronald E De Meersman
Journal:  Respir Med       Date:  2004-01       Impact factor: 3.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.